Clinical trials: Bevacizumab
Lymphoma
Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
Phase II Study of Avastin Plus Rituximab for Patients with Relapsed and Chemotherapy - or Rituxan Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma.
- Trial name
- NCT00081861
- Testing
- Avastin, Rituximab
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer
Clinical Trial in Chinese Healthy Volunteers of GB222
The primary objective of this study is to evaluate the similarity of the primary pharmacokinetic (PK) parameter AUC0-t of GB222 and bevacizumab after single administration; the secondary objective is to observe the safety and…
- Trial name
- NCT04175158
- Testing
- GB222, Bevacizumab
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Genor Biopharma Co., Ltd.
Diabetic Macular Edema
Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab
This is an open-label, Phase I/II study of Intravitreally administered 0.3mg ranibizumab in subjects with persistent Diabetic Macular Edema (DME) after recent and frequent bevacizumab (at least 2 bevacizumab intravitreal…
- Trial name
- ROTATE (NCT01845844)
- Testing
- Ranibizumab 0.3mg/0.05cc
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Malignant Solid Tumour
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
The aim of this study is the safety and efficacy of Bevacizumab plus allogeneic natural killer (NK) immunotherapy to many kinds of recurrent solid tumors.
- Trial name
- NCT02857920
- Testing
- Bevacizumab, NK immunotherapy
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Healthy Male Subjects
Study of Bevacizumab With Different Manufacturing Process in Healthy Male Subjects
The purpose of this study is to evaluate the pharmacokinetic similarity of bevacizumab with different manufacturing process in healthy male subjects.
- Trial name
- NCT05005455
- Testing
- bevacizumab with new manufacturing process., bevacizumab with old manufacturing process.
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Intraocular Pressure Change in Intravitreal Injection
Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection
To assess the effect of prophylactic antiglaucoma agents in prevention of acute intraocular pressure rise after intravitreal injection.
- Trial name
- NCT02140450
- Testing
- Timolol, Brimonidine, Acetazolamide
- Where
- Iran
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Mashhad University of Medical Sciences
Pulmonary Arterial Hypertension, Exercise Associated Pulmonary Arterial Hypertension
Angiogenic Imaging in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a disorder of elevated pulmonary vascular resistance characterized by progressive remodeling and obliteration of vessels of the distal pulmonary circulation.
- Trial name
- AIPAH (NCT03166306)
- Testing
- PET-CT Imaging with [89Zr]-bevacizumab
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
NSCLC
Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects
The purpose of this study is to establish PK similarity in the treatment of BAT1706 and comparators.
- Trial name
- NCT03030430
- Testing
- BAT1706 injection, EU-sourced Avastin, US-sourced Avastin
- Where
- New Zealand
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Healthy
PK and Safety of SCT510
This is a randomized, double-blind, parallel-controlled phase I clinical study comparing the pharmacokinetics, safety and immunogenicity of SCT510 with bevacizumab (Avastin®) in Chinese healthy males.
- Trial name
- NCT05113511
- Testing
- SCT510, Bevacizumab
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Pharmacokinetics, Safety Issues
A Phase I Study Comparing Pharmacokinetics and Safety of Bevacizumab
The aim of the Clinical study is to evaluate the pharmacokinetic and safety profile of a new formulation of Bevacizumab (Zutrab®, Argentinian origin) when compared to two already marketed formulations of Bevacizumab Avastin®…
- Trial name
- NCT03919448
- Testing
- Bevacizumab
- Where
- Argentina
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Pterygium, Bevacizumab
Topical Bevacizumab for Preventing Recurrent Pterygium
The purpose of this study is to determine whether bevacizumab eye drop is effective in the treatment of recurrent pterygium.
- Conditions
- Pterygium, Bevacizumab, VEGF, Anti-VEGF
- Trial name
- NCT01311960
- Testing
- bevacizumab eye drop 0.05%, normal saline 0.9%
- Where
- Thailand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Ovarian Cancer, Fallopian Tube Cancer
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Phase I study to evaluate intraperitoneal carboplatin along with weekly intravenous paclitaxel and bevacizumab in order to establish a tolerable dose and define the toxicity of this regimen in previously untreated patients with…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, No Prior Chemotherapy
- Trial name
- NCT01220154
- Testing
- Paclitaxel, Carboplatin, Bevacizumab
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- David O'Malley
Diabetic Macular Edema
IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2 mg followed by 2q8 IAI for a total of 52 weeks…
- Trial name
- ROTATED (NCT03340610)
- Testing
- Alflibercept
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Endometrial Carcinoma
Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
The purpose of this study is to find out whether the addition of a drug called Avastin (avastin) to the two-drug combination of carboplatin and paclitaxel shrinks tumors better than the two-drug combination alone in the treatment…
- Trial name
- NCT00879359
- Testing
- carboplatin, paclitaxel, and bevacizumab
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Healthy
Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers
Double-blind, single-dose, three-treatment, parallel group design PK comparability study of MYL-1402O solution manufactured for Mylan compared to US and EU marketed Avastin® solution (bevacizumab).
- Trial name
- NCT02469987
- Testing
- MYL-1402O, US marketed Avastin(R), EU marketed Avastin(R)
- Where
- Netherlands
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Mylan Inc.
Proliferative Diabetic Retinopathy
Intravitreal Bevacizumab vs Laser vs Combination of Bevacizumab and Modified Laser in PDR
In this randomized 3-armed clinical trial, 105 eyes with PDR will be included and divided randomly into 3 groups: IVB group (35 eyes) that receive 4 monthly IVB injections and then rescue IVB, PRP group (35 eyes) that undergo…
- Trial name
- NCT04800679
- Testing
- receive 4 monthly IVB injections and then rescue IVB, PRP group, IVB injections and a modified laser
- Where
- Iran
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Healthy
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects
Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Bevacizumab
- Trial name
- NCT02453672
- Testing
- SB8, EU sourced Avastin®, US Sourced Avastin®
- Where
- Belgium
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Samsung Bioepis Co., Ltd.
Diabetic Macular Edema
Pain and Visual Outcome in Intravitreal Bevacizumab Injection
In this double blind clinical trial, 1000 patients suffering from diabetic macular edema, age-related macular degeneration, neovascularization due to proliferative diabetic retinopathy and cystoid macular edema secondary to…
- Trial name
- pain & visual (NCT02790775)
- Testing
- Anti-VEGF in quadrant 1, Anti-VEGF in quadrant 2, Anti-VEGF in quadrant 3
- Where
- Iran
- Volunteers
- 1,004 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Non-small Cell Lung Cancer Stage II, Bevacizumab
Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases
A multicenter, single-arm, open study to evaluate the safety and efficacy of Serplulimab in combination with bevacizumab and first-line chemotherapy in driver negative non-squamous NSCLC patients with brain metastases
- Conditions
- Non-small Cell Lung Cancer Stage II, Bevacizumab, Immunotherapy, Brain Metastases
- Trial name
- SUPER BRAIN (NCT05807893)
- Testing
- Serplulimab combined with bevacizumab and first-line chemotherapy
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Macular Degeneration
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
The purpose of this study is to explore the combination of PDT with verteporfin at reduced and standard fluence rates, in conjunction with bevacizumab, in the treatment of subfoveal CNV of all subtypes with a high percentage of…
- Trial name
- NCT00403442
- Testing
- Verteporfin Therapy/ Drug: Bevacizumab
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York